Ken Griffin C4 Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.43 - $7.38 $160,366 - $267,156	36,200 Added 74.03%	85,100 $485,000
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $19,035 - $38,070	-4,700 Reduced 8.77%	48,900 $225,000
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $208,820 - $433,400	-39,400 Reduced 42.37%	53,600 $437,000
Q4 2023 Feb 14, 2024	BUY	$1.18 - $6.03 $99,592 - $508,932	84,400 Added 981.4%	93,000 $525,000
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $41,811 - $89,859	-23,100 Reduced 72.87%	8,600 $15,000
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $6,325 - $8,671	2,300 Added 7.82%	31,700 $87,000
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $61,380 - $178,596	19,800 Added 206.25%	29,400 $92,000
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $32,520 - $61,440	-6,000 Reduced 38.46%	9,600 $56,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $35,332 - $56,188	4,400 Added 39.29%	15,600 $137,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.